Login to Your Account



Clinic Roundup


Friday, September 16, 2011
Phenex Pharmaceuticals AG, of Ludwigshafen, Germany, began a Phase I trial of its candidate for non-alcoholic steatohepatitis, Px-102. The study will escalate through seven dose levels, and the first dose tested has produced no discomforts or adverse effects.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription